Clinical Experience of Lorlatinib ALK+ NSCLC Patients

Opinion
Video

Dr. Kim discusses her experience with lorlatinib in real-world settings for ALK+ NSCLC, highlighting both the benefits and challenges of incorporating it into clinical practice.

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with ALK+ non-small cell lung cancer as seen in clinical practice. The hypothetical case was co-developed by staff Medical Writers with Cancer Network/ONN.

  1. Dr.Thawani asks Dr. Kim Based on your experience, how has lorlatinib performed in real-world settings?
  • What are the benefits and challenges of incorporating lorlatinib into practice?
Recent Videos
2 experts are featured in this series.
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
4 experts in this video
2 experts are featured in this series.
4 experts in this video
5 experts are featured in this series
5 experts are featured in this series
Related Content